SETD2 and renal cell carcinoma: A recent study utilizing the Genomics of Drug Sensitivity in Cancer (GDSC) database identified that RCC cells with mutated VHL or SETD2 were sensitive to the small molecule PIK3β inhibitor TGX221 [27].